Advisors Recommend BioMarin’s Vimizim, Despite Call for More Info

Washington Drug Letter
The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee strongly urged approval of BioMarin’s orphan drug Vimizim to treat the rare disease Mucopolysaccharidosis Type IVA, overriding agency concerns of limited supportive data.

To View This Article:


Buy This Article Now

Add this article to your cart for $25.00